Arcellx Inc.
Arcellx Reports Positive Financial Results for Fiscal Year 2024
Summary
Arcellx, Inc. reported financial results for the fiscal year ended December 31, 2024, highlighting positive preliminary data from its Phase 2 pivotal iMMagine-1 study of anito-cel in patients with relapsed or refractory multiple myeloma (RRMM). The data showed a 97% overall response rate and 62% complete response rate at a median follow-up of 9.5 months. Arcellx ended the quarter with $626 million in cash, cash equivalents, and marketable securities, anticipating its cash runway to extend into 2027. The company also reported collaboration revenue of $107.9 million for the full year, with research and development expenses increasing to $157.1 million.
Profitelligence Alerts
Get alerts for ACLX
Be first to know when Arcellx Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Arcellx Inc.
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to harness the power of the immune system through its proprietary D-Domain technology platform, which is designed to improve the efficacy and safety of cell-based treatments. Arcellx focuses on targeting malignant cells with precision, thereby enhancing therapeutic outcomes and minimizing adverse effects. Operating within the highly complex and rapidly evolving biotechnology sector, Arcellx significantly contributes to advancements in life sciences and medical treatments. Given its commitment to pioneering scientific discoveries, the company represents a significant player in the push towards personalized medicine and novel cancer therapies. Through collaboration with academic institutions and strategic partnerships, Arcellx endeavors to accelerate the development and commercialization of its pipeline products, aiming to bring life-changing treatments to patients worldwide. Its research-intensive approach and focus on addressing unmet medical needs position Arcellx as an impactful entity in the biopharmaceutical landscape.
Official SEC Documents
Advertisement